John R. Christin

John R. Christin

Auto-generated profile, based on publicly available information

John R. Christin

Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2016 in Science
Verified
Journal Article
Open access
PDF file
AWAnna Z. Wec
Anna Z. Wec
ENElisabeth K. Nyakatura
Elisabeth K. Nyakatura
AHAndrew S. Herbert
Andrew S. Herbert
KHKatie A. Howell
Katie A. Howell
FHFrederick W. Holtsberg
Frederick W. Holtsberg
KCKartik Chandran
Kartik Chandran
Treating Ebola with a Trojan horse: The recent major Ebola virus outbreak in West Africa high-lighted the need for effective therapeutics against this and other filoviruses. Neutralizing ebolaviruses with antibodies is a challenge because the viruses bind their entry receptor, NPC1, inside the cell within endosomes rather than on the cell surface. Furthermore, enzymes in endosomes cleave the Ebola virus surface glycoprotein (GP) to reveal its receptor binding site. Wec et al. now report a bispecific antibody strategy targeting all known ebolaviruses that overcomes this problem (see the Perspective by Labrijn and Parren). They coupled an antibody specific for a conserved, surface-exposed epitope of GP to antibodies that recognize either NPC1 or the NPC1 binding site on GP. Treating mice therapeutically with these antibodies allowed them to survive otherwise lethal ebolavirus infection. Science , this issue p. 350 ; see also p. 284

1 March 2017 in Cell Reports
Verified
Journal Article
Open access
CWChunhui Wang
Chunhui Wang
JCJohn R. Christin
John R. Christin
MOMaja H. Oktay
Maja H. Oktay
WGWenjun Guo
Wenjun Guo
Delineating the mammary differentiation hierarchy is important for the study of mammary gland development and tumorigenesis. Mammary luminal cells are considered a major origin of human breast cancers. However, how estrogen-receptor-positive (ER+) and ER- luminal cells are developed and maintained remains poorly understood. The prevailing model suggests that a common stem/progenitor cell generates both cell types. Through genetic lineage tracing in mice, we find that SOX9-expressing cells specifically contribute to the development and maintenance of ER- luminal cells and, to a lesser degree, basal cells. In parallel, PROM1-expressing cells give rise only to ER+ luminal cells. Both SOX9+ and PROM1+ cells specifically sustain their respective lineages even after pregnancy-caused tissue remodeling or serial transplantation, demonstrating characteristic properties of long-term repopulating stem cells. Thus, our data reveal that mouse mammary ER+ and ER- luminal cells are two independent lineages that are maintained by distinct stem cells, providing a revised mammary epithelial cell hierarchy.

1 May 2017 in Cell Stem Cell
Verified
Journal Article
Closed access
HPHalley Pierce
Halley Pierce
DZDachuan Zhang
Dachuan Zhang
CMClaire Magnon
Claire Magnon
DLDaniel Lucas
Daniel Lucas
JCJohn R. Christin
John R. Christin
PFPaul S. Frenette
Paul S. Frenette

23 October 2017 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
SDSara K. Donnelly
Sara K. Donnelly
RCRamon Cabrera
Ramon Cabrera
SMSerena P.H. Mao
Serena P.H. Mao
JCJohn R. Christin
John R. Christin
Bin WuBin Wu
Bin Wu
LHLouis Hodgson
Louis Hodgson
The initial step of metastasis is the local invasion of tumor cells into the surrounding tissue. Invadopodia are actin-based protrusions that mediate the matrix degradation necessary for invasion and metastasis of tumor cells. We demonstrate that Rac3 GTPase is critical for integrating the adhesion of invadopodia to the extracellular matrix (ECM) with their ability to degrade the ECM in breast tumor cells. We identify two pathways at invadopodia important for integrin activation and delivery of matrix metalloproteinases: through the upstream recruiter CIB1 as well as the downstream effector GIT1. Rac3 activity, at and surrounding invadopodia, is controlled by Vav2 and βPIX. These guanine nucleotide exchange factors regulate the spatiotemporal dynamics of Rac3 activity, impacting GIT1 localization. Moreover, the GTPase-activating function of GIT1 toward the vesicular trafficking regulator Arf6 GTPase is required for matrix degradation. Importantly, Rac3 regulates the ability of tumor cells to metastasize in vivo. The Rac3-dependent mechanisms we show in this study are critical for balancing proteolytic activity and adhesive activity to achieve a maximally invasive phenotype.

1 September 2016 in Cell Reports
Verified
Journal Article
Open access
ZZZheng Zhang
Zheng Zhang
JCJohn R. Christin
John R. Christin
CWChunhui Wang
Chunhui Wang
KGKai Ge
Kai Ge
MOMaja H. Oktay
Maja H. Oktay
WGWenjun Guo
Wenjun Guo
Cancer genomics has provided an unprecedented opportunity for understanding genetic causes of human cancer. However, distinguishing which mutations are functionally relevant to cancer pathogenesis remains a major challenge. We describe here a mammary stem cell (MaSC) organoid-based approach for rapid generation of somatic genetically engineered mouse models (GEMMs). By using RNAi and CRISPR-mediated genome engineering in MaSC-GEMMs, we have discovered that inactivation of Ptpn22 or Mll3, two genes mutated in human breast cancer, greatly accelerated PI3K-driven mammary tumorigenesis. Using these tumor models, we have also identified genetic alterations promoting tumor metastasis and causing resistance to PI3K-targeted therapy. Both Ptpn22 and Mll3 inactivation resulted in disruption of mammary gland differentiation and an increase in stem cell activity. Mechanistically, Mll3 deletion enhanced stem cell activity through activation of the HIF pathway. Thus, our study has established a robust in vivo platform for functional cancer genomics and has discovered functional breast cancer mutations.

1 June 2020 in Cell Reports
Verified
Journal Article
Open access
JCJohn R. Christin
John R. Christin
CWChunhui Wang
Chunhui Wang
CCChi-Yeh Chung
Chi-Yeh Chung
YLYu Liu
Yu Liu
CDChristopher Dravis
Christopher Dravis
WGWenjun Guo
Wenjun Guo
Lineage plasticity is important for the development of basal-like breast cancer (BLBC), an aggressive cancer subtype. While BLBC is likely to originate from luminal progenitor cells, it acquires substantial basal cell features and contains a heterogenous collection of cells exhibiting basal, luminal, and hybrid phenotypes. Why luminal progenitors are prone to BLBC transformation and what drives luminal-to-basal reprogramming remain unclear. Here, we show that the transcription factor SOX9 acts as a determinant for estrogen-receptor-negative (ER-) luminal stem/progenitor cells (LSPCs). SOX9 controls LSPC activity in part by activating both canonical and non-canonical nuclear factor κB (NF-κB) signaling. Inactivation of TP53 and RB via expression of SV40 TAg in a BLBC mouse tumor model leads to upregulation of SOX9, which drives luminal-to-basal reprogramming in vivo. Furthermore, SOX9 deletion inhibits the progression of ductal carcinoma in situ (DCIS)-like lesions to invasive carcinoma. These data show that ER- LSPC determinant SOX9 acts as a lineage plasticity driver for BLBC progression.